Literature DB >> 9639122

Liver biopsy is a useful predictor of response to interferon therapy in chronic hepatitis C.

K Kaserer1, R Fiedler, P Steindl, C H Müller, F Wrba, P Ferenci.   

Abstract

AIM: To evaluate the usefulness of easily assessable morphological parameters in liver biopsies in order to predict efficacy of interferon-alpha (IFN) treatment in patients with chronic hepatitis C. METHODS AND
RESULTS: Inflammatory activity and fibrosis (according to Scheuer), and the hepatic iron content (according to Rowe and DiBisceglie) were assessed in pre-treatment liver biopsies of 73 de novo patients with chronic hepatitis C. Furthermore the presence of fat, lymphoid aggregates, and bile duct lesions was evaluated. With respect to IFN therapy patients were classified as responders alanine aminotransferase (ALT) normal and negative hepatitis C virus (HCV) RNA in serum at the end of treatment, n = 33) or non-responders (n = 40). Non-responders had more advanced fibrosis (P = 0.0001) and more extensive iron storage (P = 0.0008) than responders. In contrast absence of stainable iron was frequently (46%) associated with sustained response. Absence of fat droplets in hepatocytes was associated with response (P = 0.0001). Stepwise logistic regression analysis indicated that the stage of fibrosis, the hepatic iron grade, and the presence or absence of fat were independent predictors of response.
CONCLUSIONS: Liver biopsy provides useful information for selection of patients with hepatitis C for IFN therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9639122     DOI: 10.1046/j.1365-2559.1998.00413.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  13 in total

1.  The close linkage between the elasticity modulus measured by real-time mapping shear wave elastography and the presence of hepatocellular carcinoma in patients with a sustained virological response to interferon for chronic hepatitis C.

Authors:  Yasuharu Imai; Jun-Ichi Taira; Mayumi Okada; Mayumi Ando; Takatomo Sano; Yuhki Miyata; Katsutoshi Sugimoto; Ikuo Nakamura; Fuminori Moriyasu
Journal:  J Med Ultrason (2001)       Date:  2014-12-28       Impact factor: 1.314

2.  Optimizing treatment for African Americans and Latinos with HIV/AIDS.

Authors:  Richard O Butcher; Rodney G Hood; Wilbert C Jordan
Journal:  J Natl Med Assoc       Date:  2005-08       Impact factor: 1.798

3.  The effect of processing on liver biopsy core size.

Authors:  Thomas R Riley; Francesca M Ruggiero
Journal:  Dig Dis Sci       Date:  2008-02-14       Impact factor: 3.199

4.  Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1.

Authors:  M J Walsh; J R Jonsson; M M Richardson; G M Lipka; D M Purdie; A D Clouston; E E Powell
Journal:  Gut       Date:  2005-11-18       Impact factor: 23.059

5.  Routine blood tests to predict liver fibrosis in chronic hepatitis C.

Authors:  Yung-Yu Hsieh; Shui-Yi Tung; Kamfai Lee; Cheng-Shyong Wu; Kuo-Liang Wei; Chien-Heng Shen; Te-Sheng Chang; Yi-Hsiung Lin
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

6.  Interferon responsiveness in patients infected with hepatitis C virus 1b differs depending on viral subtype.

Authors:  I Nakano; Y Fukuda; Y Katano; H Toyoda; K Hayashi; T Hayakawa; T Kumada; S Nakano
Journal:  Gut       Date:  2001-08       Impact factor: 23.059

Review 7.  Non-alcoholic fatty liver disease: an emerging pathological spectrum.

Authors:  Elie Serge Zafrani
Journal:  Virchows Arch       Date:  2003-12-18       Impact factor: 4.064

8.  Hepatitis C comorbidities affecting the course and response to therapy.

Authors:  Abdel-Rahman El-Zayadi
Journal:  World J Gastroenterol       Date:  2009-10-28       Impact factor: 5.742

Review 9.  Hepatic steatosis: a benign disease or a silent killer.

Authors:  Abdel-Rahman El-Zayadi
Journal:  World J Gastroenterol       Date:  2008-07-14       Impact factor: 5.742

10.  Low dose ribavirin for treatment of hepatitis C virus infected thalassemia major patients; new indications for combination therapy.

Authors:  Seyed Vahid Tabatabaei; Seyed Moayed Alavian; Maryam Keshvari; Bita Behnava; Seyyed Mohammad Miri; Pegah Karimi Elizee; Farhad Zamani; Sedigheh Amini Kafiabad; Ahmad Gharehbaghian; Bashir Hajibeigy; Kamran Bagheri Lankarani
Journal:  Hepat Mon       Date:  2012-06-30       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.